Salarius Therapeutics

Salarius Therapeutics is a clinical-stage biotechnology company focused on developing epigenetic-based therapies and next-generation protein degraders for patients with cancer. The company's lead candidate, seclidemstat, is a potent, oral small molecule inhibitor of LSD1 being investigated in clinical trials for Ewing sarcoma and other advanced solid tumors. Salarius is also leveraging its targeted protein degradation platform to develop molecular glue degraders, including SP-3164, which targets Ikaros and Aiolos for the treatment of hematologic malignancies. By focusing on high-unmet-need oncology indications, the company aims to provide transformative treatments through the modulation of gene expression and protein stability.